Cannabis Drug Epidiolex Maker GW Pharma Raises $345 Million on Market

Oct 6, 2018 | Cannabis, GW Pharmaceuticals

Sam Wood for the Philadelphia Inquirer notes that the FDA approved cannabidiol (CBD) Epidiolex. Children’s Hospital of Philadelphia demonstrated that Epidiolex helped control certain rare forms of pediatric epilepsy. Mr. Wood writes that recently the DEA “rescheduled the drug to become a Schedule 5 substance.”  This is a change as all cannabis-based product are considered Schedule 1 by the DEA.



Pin It on Pinterest